Published in Int J Gynecol Cancer on January 01, 2015
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med (1989) 3.44
Medical admission order sets to improve deep vein thrombosis prophylaxis rates and other outcomes. J Hosp Med (2009) 2.49
Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol (2006) 2.31
Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism. Cochrane Database Syst Rev (2013) 1.88
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.54
Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol (2009) 1.47
Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist (2003) 1.13
The natural history of postoperative venous thromboemboli in gynecologic oncology: a prospective study of 382 patients. Am J Obstet Gynecol (1984) 1.04
Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol (2012) 0.88
Prevention of venous thromboembolism in hospitalized patients: analysis of reduced cost and improved clinical outcomes. J Vasc Nurs (2013) 0.85
High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. Thromb Haemost (2013) 0.79
Primary venous thromboembolism prophylaxis in ambulatory cancer patients. Ann Pharmacother (2013) 0.79
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol (2013) 4.72
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst (2005) 4.01
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis (2012) 3.11
Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstet Gynecol (2007) 2.34
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica (2008) 2.26
P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol (2007) 2.21
Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol (2005) 2.17
Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol (2004) 2.09
Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer (2011) 2.02
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol (2010) 1.89
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer (2008) 1.88
Laparoendoscopic single-site surgery in gynecology: review of literature and available technology. J Minim Invasive Gynecol (2010) 1.86
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol (2007) 1.80
Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol (2010) 1.77
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr (2006) 1.73
Radical hysterectomy in obese and morbidly obese women with cervical cancer. Obstet Gynecol (2008) 1.70
Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int (2006) 1.70
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2007) 1.69
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol (2012) 1.65
Helicobacter pylori and idiopathic thrombocytopenic purpura. Ann Intern Med (2004) 1.65
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol Oncol (2009) 1.62
The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys (2003) 1.60
Survival in cancer patients undergoing in-hospital cardiopulmonary resuscitation: a meta-analysis. Resuscitation (2006) 1.59
Association between adiponectin, insulin resistance, and endometrial cancer. Cancer (2006) 1.55
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecol Oncol (2003) 1.50
Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol (2004) 1.49
Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol (2010) 1.48
Are women ready for the HPV vaccine? Gynecol Oncol (2006) 1.47
Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer (2006) 1.47
Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy? Gynecol Oncol (2010) 1.46
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer (2010) 1.46
Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys (2009) 1.45
Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Am J Obstet Gynecol (2006) 1.45
Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43
The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol (2005) 1.35
Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol (2006) 1.35
A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer. J Minim Invasive Gynecol (2008) 1.34
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res (2008) 1.30
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol (2004) 1.28
Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol (2011) 1.28
Rate of port-site metastasis is uncommon in patients undergoing robotic surgery for gynecological malignancies. Int J Gynecol Cancer (2011) 1.28
Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol (2005) 1.26
Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol (2008) 1.26
Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res (2012) 1.25
Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol (2007) 1.23
Primary malignant melanoma of the vagina. Obstet Gynecol (2010) 1.22
Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer. Obstet Gynecol (2009) 1.21
Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol (2010) 1.20
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol (2008) 1.19
Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood (2013) 1.19
Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res (2008) 1.18
PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood (2003) 1.17
Rate of vaginal cuff separation following laparoscopic or robotic hysterectomy. Gynecol Oncol (2010) 1.16
Trends in laparoscopic and robotic surgery among gynecologic oncologists: A survey update. Gynecol Oncol (2009) 1.14
Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol (2006) 1.14
Filamin A binding to the cytoplasmic tail of glycoprotein Ibalpha regulates von Willebrand factor-induced platelet activation. Blood (2003) 1.13
Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol (2011) 1.13
Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol (2004) 1.13
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther (2006) 1.10
Atypical sigmoid metastasis from a high-grade mixed adenocarcinoma of the ovary. Gynecol Oncol (2004) 1.10
Fertility preservation in patients with early cervical cancer: radical trachelectomy. Gynecol Oncol (2008) 1.09
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol (2007) 1.09
Imaging in cervical cancer. Cancer (2003) 1.08
Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy - a systematic literature review. Gynecol Oncol (2013) 1.08
Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol (2008) 1.07
Safety and feasibility of robotic radical trachelectomy in patients with early-stage cervical cancer. Gynecol Oncol (2009) 1.07
Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol (2005) 1.06
Has the time come for sentinel lymph node biopsy alone in radical hysterectomy patients? Gynecol Oncol (2007) 1.06
Filamin A binding stabilizes nascent glycoprotein Ibalpha trafficking and thereby enhances its surface expression. J Biol Chem (2004) 1.06
Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol (2005) 1.05
Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol (2009) 1.04